Enzymology/Molecular Biology of Aldehyde Dehydrogenase

醛脱氢酶的酶学/分子生物学

• 批准号: 7234846
• 负责人: HENRY WEINER
• 金额: $ 35.17万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-06-15 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7234846
• 关键词: Affect; Aldehyde dehydrogenase (NAD+); Aldehydes; Bone Marrow; Cell Line; Cells; Class; Code; Cultured Cells; Cyclophosphamide; Drug effect disorder; Enzymatic Biochemistry; Enzymes; Family; Genes; Goals; Human; In Vitro; Individual; Isoenzymes; Learning; Mammalian Cell; Molecular Biology; Mutation; Parents; Pathway interactions; Pharmaceutical Preparations; Physiological; Polymerase Chain Reaction; Process; Prodrugs; Property; Purpose; Rate; Reaction; Role; Screening procedure; Structure; Substrate Specificity; Techniques; Toxic effect; Work; aldehyde dehydrogenases; aldophosphamide; cell killing; cell transformation; improved; in vivo; interest; killings; member; mutant; three dimensional structure; tumor

DESCRIPTION (provided by applicant): There are 17 genes coding for various forms of human aldehyde dehydrogenase (ALDH). The physiological role of most members of the ALDH family is not known though much is known about the structure and mechanisms of a few of the isozymes. An error prone PCR mutational approach has allowed us to produce mutants of some of the isozymes that have properties that differ from those of the parent enzyme. We will build upon this finding to use the mutational approach to select for isozymes that have increased activity as well as enhanced stability as compared to the parent enzyme. The rate-limiting step is the class 1, 2 and 3 isozymes, enzymes whose structure and mechanism have been studied, are different in each enzyme form. We will introduce the mutations found with any one isozyme into the others to determine if we can increase the same step in the catalytic process. The purpose is both to learn more about what controls the rate limiting step in each isozyme and then try to improve the catalytic efficiencies in the other isozymes using information gain from a different isozyme. Isozymes with increased stability will be identified from the screening procedure and then studied both in vitro and in vivo with the goal of producing a more stable enzyme. In addition we will try to select for an enzyme with an enhanced ability to oxidize aldophophamide, a toxic aldehyde produced during the transformation of the pro-drug cyclophosphamide, a compound that will destroy some tumors. Unfortunately, the drug will kill any cell that does not have an ALDH to protect it by oxidizing the toxic aldehyde. Bone marrow is one such cell. If we can produce a mutant with enhanced activity against aldophophamide we will use cell culture work to determine if cells transformed with the more active mutant ALDH can protect the cell from the toxic effects of the compound.

描述（由申请人提供）：有17个基因编码各种形式的人醛脱氢酶（ALDH）。ALDH家族的大多数成员的生理作用尚不清楚，尽管对一些同工酶的结构和机制了解很多。一个容易出错的PCR突变的方法，使我们能够产生突变体的一些同工酶的特性，不同于那些的亲本酶。我们将建立在这一发现的基础上，使用突变的方法来选择具有增加的活性以及增强的稳定性相比，亲本酶的同工酶。限速步骤是1类、2类和3类同工酶，这些酶的结构和机制已被研究，在每种酶形式中是不同的。我们将把在任何一种同工酶中发现的突变引入到其他同工酶中，以确定我们是否可以增加催化过程中的同一步骤。其目的是了解更多关于什么控制每个同工酶的限速步骤，然后尝试使用来自不同同工酶的信息增益来提高其他同工酶的催化效率。具有增加的稳定性的同工酶将从筛选程序中鉴定，然后在体外和体内进行研究，目的是产生更稳定的酶。此外，我们将尝试选择一种具有增强氧化aldophamide能力的酶，aldophamide是一种在前药环磷酰胺转化过程中产生的有毒醛，这种化合物将破坏一些肿瘤。不幸的是，这种药物会通过氧化有毒的醛来杀死任何没有ALDH保护的细胞。骨髓就是这样一种细胞。如果我们可以产生对醛磷酰胺具有增强活性的突变体，我们将使用细胞培养工作来确定用更有活性的突变体ALDH转化的细胞是否可以保护细胞免受化合物的毒性作用。